Abstract
Currently, the evaluation and treatment of chronic inflammatory diseases relies on specific clinical signs accompanied with single or multiple marker(s) for that disease. Despite that, these diseases share a common innate immune mechanism involved upregulation of “Inflammasome” that have been proved in its implication in the pathologic mechanism (s) and direct irreversible conversion of pro-interleukin 1β and pro-interleukin 18 into active IL-1b and active IL-18 contributing in disease progression and tissue damage, suggesting a common theranostic target to reduce inflammatory mechanism.
Keywords: NLRP3, inflammasome, theranostic marker
Citation:Ghazi HF. NLRP3 Inflammasome: a promising theranostic target in inflammatory diseases. Iraqi JMS. 2018; Vol. 16(1): 1-3. doi: 10.22578/IJMS.16.1.1
Keywords: NLRP3, inflammasome, theranostic marker
Citation:Ghazi HF. NLRP3 Inflammasome: a promising theranostic target in inflammatory diseases. Iraqi JMS. 2018; Vol. 16(1): 1-3. doi: 10.22578/IJMS.16.1.1
Keywords
inflammasome
NLRP3
theranostic marker